{"id":200668,"date":"2026-11-07T15:16:11","date_gmt":"2026-11-07T15:16:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/200668\/"},"modified":"2026-11-07T15:16:11","modified_gmt":"2026-11-07T15:16:11","slug":"aha-conference-news-novo-nordisks-zeus-trial-failure-examined","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/200668\/","title":{"rendered":"AHA conference news: Novo Nordisk&#8217;s ZEUS trial failure examined"},"content":{"rendered":"<p class=\"wp-block-paragraph\">CHICAGO \u2014 Out-of-control inflammation is often called the root of all evil in cardiovascular and metabolic disease. Recent clinical trial results, <a href=\"https:\/\/www.statnews.com\/2026\/07\/31\/novo-nordisk-inflammation-heart-disease-ziltivekimab\/\" rel=\"nofollow noopener\" target=\"_blank\">described in brief in July<\/a>, showed that while an experimental drug could lower two biomarkers of inflammation, it didn\u2019t limit serious heart events in patients with severe illness.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">The Novo Nordisk study, called ZEUS, showed that the monoclonal antibody ziltivekimab reduced levels of the inflammatory cytokine interleukin-6, or IL-6, but that drop did not translate into fewer heart attacks, strokes, or deaths in the treatment group compared to those taking a placebo. Once top-line results were disclosed, Novo <a href=\"https:\/\/www.statnews.com\/2026\/09\/07\/novo-nordisk-heart-studies-inflammation-ziltivekimab\/\" rel=\"nofollow noopener\" target=\"_blank\">halted two other trials<\/a> of the drug called HERMES and ATHENA after a data monitoring committee found in September they were unlikely to succeed.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">The ZEUS results were detailed further on Saturday at the American Heart Association\u2019s scientific sessions and published simultaneously in the <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2612126\" target=\"_blank\" rel=\"noopener nofollow\">New England Journal of Medicine<\/a>.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"CHICAGO \u2014 Out-of-control inflammation is often called the root of all evil in cardiovascular and metabolic disease. Recent&hellip;\n","protected":false},"author":2,"featured_media":200669,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2759,42881,15044,4240,272,359],"class_list":["post-200668","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotechnology","tag-cardiovascular-disease","tag-clinical-trials","tag-drug-development","tag-novo-nordisk","tag-stat"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/200668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=200668"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/200668\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/200669"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=200668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=200668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=200668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}